Associated Papers
SATB2 Induces Malignant Transformation and Cancer Stem Cell Characteristics, and Inhibition of Its Expression Reverses Drug Resistance in Mesothelioma.
Brown C et al.
Cells, 2026
Characterization of BRCA1-Associated Protein-1 (BAP1) Aggregation Properties Induced by Cancer-Associated Mutations.
Hsiao LC et al.
Chembiochem : a European Journal of Chemical Biology, 2025
Saturation genome editing of BAP1 functionally classifies somatic and germline variants.
Waters AJ et al.
Nature Genetics, 2024
The BAP1 nuclear deubiquitinase is involved in the nonhomologous end-joining pathway of double-strand DNA repair through interaction with DNA-PK.
Sato H et al.
Oncogene, 2024
BAP1 Malignant Pleural Mesothelioma Mutations in Caenorhabditis elegans Reveal Synthetic Lethality between ubh-4/BAP1 and the Proteasome Subunit rpn-9/PSMD13.
Martínez-Fernández C et al.
Cells, 2023
BAP1 loss induces mitotic defects in mesothelioma cells through BRCA1-dependent and independent mechanisms.
Singh A et al.
Oncogene, 2023
BAP1 and YY1 regulate expression of death receptors in malignant pleural mesothelioma.
Ishii Y et al.
The Journal of Biological Chemistry, 2021
Targeted Therapy of Papillary Thyroid Cancer: A Comprehensive Genomic Analysis.
Hescheler DA et al.
Frontiers in Endocrinology, 2021
PR-DUB maintains the expression of critical genes through FOXK1/2- and ASXL1/2/3-dependent recruitment to chromatin and H2AK119ub1 deubiquitination.
Kolovos P et al.
Genome Research, 2020
BAP1 Missense Mutations in Cancer: Friend or Foe?
Okonska A et al.
Trends in Cancer, 2019
A bidentate Polycomb Repressive-Deubiquitinase complex is required for efficient activity on nucleosomes.
Foglizzo M et al.
Nature Communications, 2018
Cancer associated missense mutations in BAP1 catalytic domain induce amyloidogenic aggregation: A new insight in enzymatic inactivation.
Bhattacharya S et al.
Scientific Reports, 2015
Tumor suppressor ASXL1 is essential for the activation of INK4B expression in response to oncogene activity and anti-proliferative signals.
Wu X et al.
Cell Research, 2015
Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in renal cell carcinoma.
Piva F et al.
Oncotarget, 2015
Functional differences between wild-type and mutant-type BRCA1-associated protein 1 tumor suppressor against malignant mesothelioma cells.
Hakiri S et al.
Cancer Science, 2015
Prevalence of BRCA-1 associated protein 1 germline mutation in sporadic malignant pleural mesothelioma cases.
Rusch A et al.
Lung Cancer (amsterdam, Netherlands), 2015
BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies.
Piva F et al.
Expert Review of Molecular Diagnostics, 2015
Germline mutations in BAP1 impair its function in DNA double-strand break repair.
Ismail IH et al.
Cancer Research, 2014
Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma.
Yoshikawa Y et al.
Cancer Science, 2012
The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma.
Bott M et al.
Nature Genetics, 2011
An emerging model for BAP1's role in regulating cell cycle progression.
Eletr ZM et al.
Cell Biochemistry and Biophysics, 2011
The potential role of ubiquitin c-terminal hydrolases in oncogenesis.
Fang Y et al.
Biochimica Et Biophysica Acta, 2010
BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization.
Ventii KH et al.
Cancer Research, 2008
AlphaMissense Predictions and ClinVar Annotations: A Deep Learning Approach to Uveal Melanoma.
Taylor Gonzalez DJ et al.
Ophthalmology Science, 0